Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Share Price
Equities
6990
CNE1000062J1
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 519.00 HKD | +6.97% |
|
+3.08% | +32.33% |
| Capitalization | 105B 121B 15.45B 13.08B 12.06B 11.38B 21.22B 1,440B 21.56B 141B 55.39B 691B 57.95B 56.73B 2,454B | P/E ratio 2025 |
-208x | P/E ratio 2026 * | -617x |
|---|---|---|---|---|---|
| Enterprise value | 102B 118B 15.02B 12.72B 11.73B 11.06B 20.64B 1,400B 20.97B 138B 53.86B 672B 56.35B 55.17B 2,387B | EV / Sales 2025 |
38.4x | EV / Sales 2026 * | 37.2x |
| Free-Float |
59.59% | Yield 2025 * |
-
| Yield 2026 * | - |
| 1 day | +6.97% | ||
| 1 week | +3.08% | ||
| Current month | +12.83% | ||
| 1 month | +31.46% | ||
| 3 months | +11.28% | ||
| 6 months | +16.32% | ||
| Current year | +32.33% |
| 1 week | 477.6 |  | 527.5 |
| 1 month | 388.4 | | 527.5 |
| Current year | 339.6 | | 527.5 |
| 1 year | 275 | | 581 |
| 3 years | 60.6 | | 581 |
| 5 years | 60.6 | | 581 |
| 10 years | 60.6 | | 581 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jun You Ge
CEO | Chief Executive Officer | 54 | 28/02/2022 |
Ze Jian Zhou
DFI | Director of Finance/CFO | 43 | 16/08/2022 |
Xiao Ping Jin
CTO | Chief Tech/Sci/R&D Officer | 49 | 05/09/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Ge Xin Liu
CHM | Chairman | 75 | 28/02/2022 |
Jun You Ge
BRD | Director/Board Member | 54 | 24/02/2022 |
Si Chuan Liu
BRD | Director/Board Member | 42 | 21/11/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +6.97% | +3.08% | +61.68% | - | 14.44B | |
| +0.71% | +5.88% | +33.96% | +101.48% | 51.73B | |
| +0.26% | +5.46% | +101.15% | +24.51% | 47.14B | |
| -4.43% | -8.48% | +106.27% | +719.42% | 33.11B | |
| +1.47% | +8.42% | +0.84% | -19.98% | 24.89B | |
| -0.59% | +5.77% | +74.53% | -32.48% | 19.66B | |
| -0.22% | +2.82% | +42.23% | -36.70% | 17.86B | |
| +6.89% | +4.91% | +69.52% | +212.29% | 16.22B | |
| +1.06% | +12.39% | -14.13% | +1,221.25% | 16.17B | |
| -1.36% | -0.54% | +60.99% | +101.50% | 12.04B | |
| Average | +1.11% | +4.43% | +53.70% | +254.59% | 25.33B | |
| Weighted average by Cap. | +0.58% | +4.15% | +58.47% | +221.27% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 1.94B 2.23B 285M 241M 223M 210M 391M 26.56B 398M 2.61B 1.02B 12.75B 1.07B 1.05B 45.28B | 2.75B 3.16B 403M 341M 315M 297M 553M 37.55B 562M 3.69B 1.44B 18.03B 1.51B 1.48B 64.01B |
| Net income | -513M -589M -75.17M -63.67M -58.71M -55.36M -103M -7.01B -105M -689M -270M -3.36B -282M -276M -11.94B | -176M -202M -25.74M -21.81M -20.11M -18.96M -35.37M -2.4B -35.94M -236M -92.32M -1.15B -96.59M -94.57M -4.09B |
| Net Debt | -2.89B -3.33B -425M -360M -332M -313M -583M -39.57B -593M -3.89B -1.52B -19B -1.59B -1.56B -67.45B | -3.18B -3.66B -467M -396M -365M -344M -642M -43.53B -652M -4.28B -1.67B -20.9B -1.75B -1.72B -74.2B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/04/26 | 519.00 $ | +6.97% | 893,992 |
| 14/04/26 | 485.20 $ | -0.41% | 507,318 |
| 13/04/26 | 487.20 $ | -1.18% | 329,405 |
| 10/04/26 | 493.00 $ | +1.61% | 577,773 |
| 09/04/26 | 485.20 $ | -0.37% | 453,856 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 6990 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition